The Age
·general
·23 hours ago
Amplia targets ovarian cancer in new clinical protein inhibitor trial
Amplia Therapeutics is aggressively broadening its clinical reach, unveiling a major new collaboration to throw its lead drug candidate, narmafotinib, into the ring against ovarian cancer. The company has inked a deal with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to launch a new clinical study to evaluate its protein-inhibiting drug in combination with conventional chemotherapy.
Summary by Glance · The Age
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI